Neoprobe leaps on US FDA acceptance of cancer diagnostic agent NDA
This article was originally published in Clinica
Executive Summary
Shares of Neoprobe jumped as high as 21%, or 55 cents, on 20 October, after the firm revealed that the US FDA accepted the company's new drug application (NDA) for its radioactive diagnostic tracing agent Lymphoseek (tilmanocept) for use in intraoperative lymphatic mapping (ILM). This surgical oncology procedure is used primarily in patients with breast cancer and melanoma to determine if disease has spread to the lymph nodes.